Short‐Term Effects of Exogenous Angiotensin II on Plasma Fibrinolytic Balance in Normal Subjects

Lottermoser, Katja; Hertfelder, Hans-Jörg; Gohlke, Peter; Vetter, Hans; Düsing, Rainer

doi:10.1081/ceh-120027328

Cited by 12 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, it is often claimed that elevated Ang II is associated with increased PAI-1. In contrast, studies by others and us show decreased PAI-1 during Ang II infusion [17,18]. Although it cannot be ruled out that Ang II may stimulate PAI-1 production in the longterm setting, we found no short-term effect of Ang II on circulating PAI-1.…”

Section: Discussioncontrasting

confidence: 81%

Infusion of angiotensin II increases fibrinolysis in healthy individuals but not in patients with familial combined hyperlipidemia

Ekholm

Kahan²,

Jörneskog

et al. 2016

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Impaired fibrinolysis is related to insulin resistance, also a characteristic feature of familial combined hyperlipidemia (FCHL). The renin-angiotensin (Ang) system is upregulated with insulin resistance, and there is crosstalk between Ang II and insulin-signalling pathways. We studied the fibrinolytic effects of a 3-h systemic Ang II infusion in 16 patients with FCHL and 16 controls, and placebo infusion in eight individuals. Baseline plasminogen activator inhibitor-1 (PAI-1) activity, plasmin-antiplasmin complex, insulin resistance and C-reactive protein were higher in patients with FCHL than in controls. PAI-1 activity decreased during Ang II, similar in patients with FCHL and controls, and by placebo. Plasmin-antiplasmin complex was unaffected by Ang II in FCHL but increased in controls. Patients with FCHL show signs of insulin resistance, low-grade inflammation and impaired fibrinolysis. Ang II enhances fibrinolysis in controls but not in patients with FCHL, suggesting that patients with FCHL are not capable of increasing tissue plasminogen activator activity in response to Ang II. Ang II has no short-term effects on PAI-1 activity.

show abstract

Section: Discussioncontrasting

confidence: 81%

Infusion of angiotensin II increases fibrinolysis in healthy individuals but not in patients with familial combined hyperlipidemia

Ekholm

Kahan²,

Jörneskog

et al. 2016

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…Some reports have suggested that AT 1 receptor antagonists have no effect on PAI-1 activity and fibrinolysis in healthy subjects and patients with mild hypertension [19,20]. It is of interest that candesartan treatment reduces PAI-1 expression in spontaneously hypertensive rats, but has no effect in Wistar-Kyoto rats [6] and that AT 1 receptor blockers reduce PAI-1 activity in hypertensive patients [8]; these results suggest that the effect of AT 1 receptor antagonists on fibrinolytic balance may only be of importance in a pathologic state.…”

Section: Discussionmentioning

confidence: 98%

Reduction of adhesion formation by an angiotensin type 1 receptor antagonist

Tokinaga

Kimoto

Ogawa

et al. 2010

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“…A first study in vivo, in which four normotensive subjects and six hypertensive patients received an intravenous infusion of angiotensin II demonstrated a rapid increase in circulating levels of PAI-1 [Ridker et al 1993]. However, other study groups were unable to confirm an increase in PAI-1 levels in response to angiotensin II infusion or following ARB treatment (Figure 3) [Lottermoser et al 2000[Lottermoser et al , 2004Skurk et al 2004].…”

Section: Is There Evidence Of Effects Beyond Bp Lowering?mentioning

confidence: 99%

Pharmacological interventions into the renin–angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering

Düsing¹

2016

Therapeutic Advances in Cardiovascular Disease

Self Cite

View full text Add to dashboard Cite

Hypertension is recognized as an important risk factor for cardiovascular morbidity and mortality. Lowering of blood pressure has been shown to minimize the risk of cardiovascular events, with the majority of antihypertensives demonstrating a similar ability to reduce coronary events and stroke for a given reduction in blood pressure. Agents that modify the activity of the renin-angiotensin system (RAS) have been proposed to exhibit additional effects that might go beyond simple blood pressure lowering. The RAS is a crucial system that regulates extracellular fluid volume and blood pressure. Proposed potential benefits of RAS blockade that go beyond blood pressure lowering include a reduction in platelet aggregation and thrombosis, blunting of cardiac and vascular remodeling, favorable metabolic effects and reno- and cerebro-protection. However, factors such as treatment adherence, duration of action of antihypertensive agents and differences in effects on central versus brachial blood pressure may also result in apparent differences in efficacy of different antihypertensives. The aim of this review article is to examine the available data from clinical studies of antihypertensive drugs for evidence of effects that might legitimately be claimed to go beyond simple blood pressure lowering.

show abstract

Short‐Term Effects of Exogenous Angiotensin II on Plasma Fibrinolytic Balance in Normal Subjects

Abstract: In conclusion, in healthy volunteer subjects, short-term infusion of Angiotensin II without and with concomitant administration of an AT1-receptor antagonist has no effect on PAI-1 activities and plasma concentrations.

Cited by 12 publications

References 30 publications

Infusion of angiotensin II increases fibrinolysis in healthy individuals but not in patients with familial combined hyperlipidemia

Infusion of angiotensin II increases fibrinolysis in healthy individuals but not in patients with familial combined hyperlipidemia

Reduction of adhesion formation by an angiotensin type 1 receptor antagonist

Pharmacological interventions into the renin–angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering

Contact Info

Product

Resources

About